Novo Nordisk to Cut Ozempic and Wegovy Prices by Up to 50% Starting 2027

1-Minute Brief

Novo Nordisk will reduce prices of key weight-loss and diabetes drugs for insured U.S. patients beginning in 2027.

Key Facts

• Novo Nordisk plans to reduce list prices of GLP-1 drugs, including Ozempic and Wegovy, by up to 50% in the U.S.
• The price reduction will start in 2027, with the drugs priced at $675 per month.
• The cuts aim to improve affordability for insured patients, especially those with high-deductible health plans or co-insurance.
• Approximately one in eight Americans are reported to be taking weight-loss drugs like Ozempic and Wegovy.
• Novo Nordisk is a Danish pharmaceutical company specializing in diabetes and weight-loss treatments.

What Happened

Novo Nordisk announced it will lower the list prices of its GLP-1 drugs, including Ozempic and Wegovy, by up to 50% in the United States starting in 2027. The company stated the new price will be $675 per month, aiming to make these medications more accessible to insured patients, particularly those with high-deductible or co-insurance health plans.

Why It Matters

The price reduction could increase access to popular weight-loss and diabetes medications for millions of insured Americans, potentially impacting treatment affordability and usage. Given the reported high demand for these drugs, the move may influence market dynamics and healthcare costs related to obesity and diabetes management.